Fig. 5
From: Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
Binding mechanisms and epitope mapping of PD-1, CTLA-4, and LAG-3 inhibiting bispecific antibodies (bsAbs). A This panel illustrates the binding mechanism of cadonilimab, a bispecific antibody targeting both CTLA-4 and PD-1. B The binding interface of reozalimab, which simultaneously targets PD-L1 and PD-1. C This panel details the binding interface of lorigerlimab, which targets both PD-1 and CTLA-4. D The binding interface of tebotelimab, a bispecific antibody targeting PD-1 and LAG-3